BIOPHYTIS (EPA:ALBPS) - Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on SARA-INT, the Phase 2b clinical study, at the 10th International Conference on Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France
Biophytis to Present the Preliminary Results of SARA-OBS and its Impact on
SARA-INT, the Phase 2b clinical study, at the 10th International Conference on
Frailty and Sarcopenia Research (ICFSR 2020) in Toulouse, France
Paris (France), Cambridge (Massachusetts, United States), March 3rd, 2020, 8:00
AM CET - Biophytis SA (Euronext Growth Paris: ALBPS), a clinical-stage
biotechnology company with a primary focus on the development of its lead drug
candidate, Sarconeos (BIO101) for the treatment of neuromuscular diseases,
announces that Biophytis management will make a presentation titled, "SARA
PROGRAM: PRELIMINARY FINDINGS & IMPLICATIONS FROM SARA-OBS STUDY AND ITS IMPACT
ON SARA-INT STUDY" at the 10th International Conference on Frailty and
Sarcopenia Research (ICFSR 2020). The Conference is taking place between 11 and
13th March 2020 in Toulouse, France.
Biophytis' clinical development plan for Sarconeos (BIO101) for the treatment
of sarcopenia comprises:
* SARA-PK, a Phase 1 clinical trial that showed safety and tolerability in
older healthy volunteers. The trial completed in 2017.
* SARA-OBS, an observational trial that was completed in Q2 2019, and
* SARA-INT, an ongoing international Phase 2b trial with a 6-month follow-up
period that is currently recruiting patients in the US and Europe. The
primary endpoint of the study is the 400-meter walking test gait speed.
Biophytis presentation will:
* Outline the SARA-OBS study, which was designed to characterize, pre-recruit
and confirm the optimal patient population for the SARA-INT trial, and
* Provide data on the preliminary baseline characteristics and changes from
baseline of the first set of SARA-OBS patients.
In addition, insights on the SARA-INT recruitment strategies, including
inclusion criteria, as well as the baseline characteristics of the first
patients, will be discussed.
The presentation will be made Wednesday March 11th at 12:20 PM CET.
Biophytis SA is a clinically staged biotechnology company specializing in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age-related diseases, particularly
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of Sarconeos (BIO101) is
being developed for the treatment of Duchenne myopathy (DMD) for which the
company received IND status by the U.S. Food and Drug Administration (FDA) in
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.
This press release contains forward-looking statements. While the Company
considers its projections to be based on reasonable assumptions, these
forward-looking statements may be called into question by a number of hazards
and uncertainties, so that actual results may differ materially from those
anticipated in such forward-looking statements. For a description of the risks
and uncertainties likely to affect the results, BIOPHYTIS' financial position,
performance or achievements and thus cause a change from the forward-looking
statements, please refer to the "Risk Factors" section of the Company's Equity
Admission Prospectus for listing on the Euronext Growth market in Paris filed
with the AMF and available on the AMF (www.amf-france.org) and BIOPHYTIS
websites ( www.biophytis.com).
This press release, and the information contained in it, does not constitute an
offer to sell or subscribe, nor the solicitation of a purchase or subscription
order, of BIOPHYTIS shares in any country. The elements contained in this
communication may contain forward-looking information involving risks and
uncertainties. The Company's actual achievements may differ materially from
those anticipated in this information due to different risk and uncertainty
factors. This press release was written in French and English; If there is a
difference between the texts, the French version will prevail.